Quinaprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC50 = 0.06 nM) and an active metabolite of the ACE inhibitor prodrug quinapril .1,2 It inhibits calcium overload and rod to round cell shape change induced by lysophosphatidylcholine (LPC) in isolated rat cardiomyocytes when used at concentrations of 20 and 50 µM.2 Quinaprilat (3 µg/kg) reduces the frequency of ventricular fibrillation in a dog model of myocardial ischemia and reperfusion injury.3 It also reduces blood pressure and proteinuria in rat models of uranyl nitrate- or 5/6 nephrectomy-induced chronic renal failure when administered at a dose of 0.1 mg/kg.4
1.Perich, R.B., Jackson, B., and Johnston, C.I.Structural constraints of inhibitors for binding at two active sites on somatic angiotensin converting enzymeEur. J. Pharmacol.266(3)201-211(1994) 2.Ma, H., Hashizume, H., Hara, A., et al.Protective effect of quinaprilat, an active metabolite of quinapril, on Ca2+-overload induced by lysophosphatidylcholine in isolated rat cardiomyocytesJpn. J. Pharmacol.79(1)17-24(1999) 3.Fujinaga, H., Wakatsuki, T., Nishikado, A., et al.Electrophysiologic effects of quinaprilat in dogs during acute myocardial ischemia and following reperfusionCoron. Artery Dis.9(10)697-701(1998) 4.Appenroth, D., Beutinger, R., Lupp, A., et al.Effects of a therapy with losartan and quinaprilat on the progression of chronic renal failure in rats after a single dose of uranyl nitrate or 5/6 nephrectomyExp. Toxicol. Pathol.54(5-6)359-366(2003)